September 30, 2016 11:19 AM EDT

Week in review: Clinton over Trump; the hubs have it; we'll always have Paris

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

TRENDING NOW

Who pays the most in biopharma? We analyzed median pay at 177 companies

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

Kidney health biotech emerges with $54M to follow in Vertex’s footsteps

Ultragenyx, Mereo’s bone disease drug fails second interim analysis, stocks plummet

Swiss and German radiopharma biotech Nuclidium collects $99M Series B

sponsored

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases